Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

Stefan K. Barta, Yiyu Zou, John Schindler, Niraj Shenoy, Tushar D. Bhagat, Ulrich Steidl, Amit Verma

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The outcome for patients with refractory or relapsed acute lymphoblastic leukemia (ALL) treated with conventional therapy is poor. Immunoconjugates present a novel approach and have recently been shown to have efficacy in this setting. Combotox is a mixture of two ricin-conjugated monoclonal antibodies (RFB4 and HD37) directed against CD19 and CD22, respectively, and has shown activity in pediatric and adult ALL. We created a murine xenograft model of advanced ALL using the NALM/6 cell line to explore whether the combination of Combotox with the cytotoxic agent cytarabine (Ara-C) results in better outcomes. In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequential administration of Ara-C and Combotox, however, was shown to be superior to concurrent administration. These findings have led to a phase I clinical trial exploring this combination in adults with relapsed or refractory B-lineage ALL (ClinicalTrials.gov identifier NCT01408160).

Original languageEnglish (US)
Pages (from-to)1999-2003
Number of pages5
JournalLeukemia and Lymphoma
Volume53
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Ricin
Immunotoxins
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoconjugates
Clinical Trials, Phase I
Cytotoxins
Heterografts
Monoclonal Antibodies
Pediatrics
Cell Line
Survival
combotox
Therapeutics

Keywords

  • Acute lymphoblastic
  • Animal model
  • Cytarabine
  • Immunoconjugate
  • Leukemia
  • Mouse
  • NOD
  • Ricin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{524b0c04878740b0882050f414c612ca,
title = "Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia",
abstract = "The outcome for patients with refractory or relapsed acute lymphoblastic leukemia (ALL) treated with conventional therapy is poor. Immunoconjugates present a novel approach and have recently been shown to have efficacy in this setting. Combotox is a mixture of two ricin-conjugated monoclonal antibodies (RFB4 and HD37) directed against CD19 and CD22, respectively, and has shown activity in pediatric and adult ALL. We created a murine xenograft model of advanced ALL using the NALM/6 cell line to explore whether the combination of Combotox with the cytotoxic agent cytarabine (Ara-C) results in better outcomes. In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequential administration of Ara-C and Combotox, however, was shown to be superior to concurrent administration. These findings have led to a phase I clinical trial exploring this combination in adults with relapsed or refractory B-lineage ALL (ClinicalTrials.gov identifier NCT01408160).",
keywords = "Acute lymphoblastic, Animal model, Cytarabine, Immunoconjugate, Leukemia, Mouse, NOD, Ricin",
author = "Barta, {Stefan K.} and Yiyu Zou and John Schindler and Niraj Shenoy and Bhagat, {Tushar D.} and Ulrich Steidl and Amit Verma",
year = "2012",
month = "10",
doi = "10.3109/10428194.2012.679267",
language = "English (US)",
volume = "53",
pages = "1999--2003",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

AU - Barta, Stefan K.

AU - Zou, Yiyu

AU - Schindler, John

AU - Shenoy, Niraj

AU - Bhagat, Tushar D.

AU - Steidl, Ulrich

AU - Verma, Amit

PY - 2012/10

Y1 - 2012/10

N2 - The outcome for patients with refractory or relapsed acute lymphoblastic leukemia (ALL) treated with conventional therapy is poor. Immunoconjugates present a novel approach and have recently been shown to have efficacy in this setting. Combotox is a mixture of two ricin-conjugated monoclonal antibodies (RFB4 and HD37) directed against CD19 and CD22, respectively, and has shown activity in pediatric and adult ALL. We created a murine xenograft model of advanced ALL using the NALM/6 cell line to explore whether the combination of Combotox with the cytotoxic agent cytarabine (Ara-C) results in better outcomes. In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequential administration of Ara-C and Combotox, however, was shown to be superior to concurrent administration. These findings have led to a phase I clinical trial exploring this combination in adults with relapsed or refractory B-lineage ALL (ClinicalTrials.gov identifier NCT01408160).

AB - The outcome for patients with refractory or relapsed acute lymphoblastic leukemia (ALL) treated with conventional therapy is poor. Immunoconjugates present a novel approach and have recently been shown to have efficacy in this setting. Combotox is a mixture of two ricin-conjugated monoclonal antibodies (RFB4 and HD37) directed against CD19 and CD22, respectively, and has shown activity in pediatric and adult ALL. We created a murine xenograft model of advanced ALL using the NALM/6 cell line to explore whether the combination of Combotox with the cytotoxic agent cytarabine (Ara-C) results in better outcomes. In our model the combination of both low- and high-dose Combotox and Ara-C resulted in significantly longer median survival. Sequential administration of Ara-C and Combotox, however, was shown to be superior to concurrent administration. These findings have led to a phase I clinical trial exploring this combination in adults with relapsed or refractory B-lineage ALL (ClinicalTrials.gov identifier NCT01408160).

KW - Acute lymphoblastic

KW - Animal model

KW - Cytarabine

KW - Immunoconjugate

KW - Leukemia

KW - Mouse

KW - NOD

KW - Ricin

UR - http://www.scopus.com/inward/record.url?scp=84865734833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865734833&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.679267

DO - 10.3109/10428194.2012.679267

M3 - Article

C2 - 22448921

AN - SCOPUS:84865734833

VL - 53

SP - 1999

EP - 2003

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -